Bruker（BRKR）株式概要
ブルカー・コーポレーションは子会社とともに科学機器、分析・診断ソリューションの開発、製造、販売を行っている。 詳細
BRKR Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bruker Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$59.56 |
| 52週高値 | US$65.30 |
| 52週安値 | US$28.53 |
| ベータ | 1.28 |
| 1ヶ月の変化 | -1.47% |
| 3ヶ月変化 | 30.36% |
| 1年変化 | 67.59% |
| 3年間の変化 | -5.26% |
| 5年間の変化 | -32.33% |
| IPOからの変化 | 158.25% |
最新ニュース
ナラティブ更新 • Aug 07
BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss
The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.Seeking Alpha • Aug 05
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking AlphaRecent updates
ナラティブ更新 • Aug 07
BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss
The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.Seeking Alpha • Aug 05
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 24
BRKR: Infection Detection Expansion Will Meet Rich Tools Sector Expectations
Bruker’s updated analyst price target of $59.75, up from $56, reflects a series of target increases into the $60 to $70 range as analysts recalibrate their models for life science and diagnostic tools stocks and incorporate what they view as reasonable earnings expectations along with improving sentiment toward the group. Analyst Commentary Recent research updates on Bruker show a wide range of price targets clustered between US$60 and US$70, with most analysts adjusting their models for the life science and diagnostic tools sector ahead of upcoming earnings reports.ナラティブ更新 • Jul 10
BRKR: Diagnostics Portfolio Momentum Will Counter Valuation And Execution Uncertainty
The analyst fair value estimate for Bruker has been raised from $53.25 to $56.00 after analysts responded to a series of higher Street price targets and updated models across diagnostics and life sciences tools coverage. Analyst Commentary Recent Street research on Bruker shows a mix of optimism and caution, with several firms updating price targets and ratings as they refresh models across diagnostics and life sciences tools coverage.ナラティブ更新 • Jun 26
BRKR: Rich Multiple And Execution Risks Will Pressure Earnings Power Into 2026
Bruker’s analyst fair value estimate has been revised from $36.80 to $35.00 as analysts weigh a richer valuation, even as several recent price target increases in the $60 to $65 range cite updated models and improving sentiment toward life science and diagnostic tools stocks. Analyst Commentary Recent Street commentary on Bruker shows a clear divide between optimistic targets and more cautious views that question how much upside is left at current prices.ナラティブ更新 • Jun 11
BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks
The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.ナラティブ更新 • May 28
BRKR: Rising Helium Costs Will Constrain Earnings Power Into 2026
Analysts have lifted their average price target on Bruker by about $1.80, citing updated assumptions that include a slightly lower discount rate, modestly higher revenue growth and profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism on long term prospects and concern about near term risks.ナラティブ更新 • May 14
BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds
Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.ナラティブ更新 • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.ナラティブ更新 • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.ナラティブ更新 • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.ナラティブ更新 • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.ナラティブ更新 • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.ナラティブ更新 • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.分析記事 • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...ナラティブ更新 • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.ナラティブ更新 • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.ナラティブ更新 • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.ナラティブ更新 • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.ナラティブ更新 • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.分析記事 • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...ナラティブ更新 • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.ナラティブ更新 • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.ナラティブ更新 • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).株主還元
| BRKR | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 3.2% | 7.4% | -1.5% |
| 1Y | 67.6% | 25.1% | 17.8% |
業界別リターン: BRKR過去 1 年間で25.1 % の収益を上げたUS Life Sciences業界を上回りました。
リターン対市場: BRKR過去 1 年間で17.8 % の収益を上げたUS市場を上回りました。
価格変動
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 10.4% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: BRKR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BRKRの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1960 | 11,085 | Frank Laukien | www.bruker.com |
ブルカー・コーポレーションは、子会社とともに科学機器、分析・診断ソリューションの開発、製造、販売を行っている。4つのセグメントで事業を展開：ブルカー・サイエンティフィック・インスツルメンツ（BSI）バイオスピン、BSIカリッド、BSIナノ、ブルカー・エナジー＆スーパーコン・テクノロジーズ。磁気共鳴分光、前臨床イメージング、バイオファーマと応用、サービスとライフサイクルサポート、統合データソリューション、自動化、ライフサイエンスツール、革新的な核磁気共鳴（NMR）と電子常磁性共鳴（EPR）製品、生体内プロセスと創薬のためのソリューション；アフターマーケットソリューション、ラボの自動化とデジタル化のためのソリューション、質量分析ソリューションとテストキット、DNAテストストリップ、蛍光ベースのPCR技術、遺伝子型と蛍光型の分子診断キット、研究、分析、プロセス分析機器とソリューション。また、ポータブル分析装置やバイオ分析検出システム、関連製品、X線装置、電子顕微鏡用分析ツール、ハンドヘルド、ポータブル、モバイル蛍光X線分析装置、原子間力顕微鏡装置、非接触ナノメートル分解能ソリューショントポグラフィー、自動X線計測、自動AFM欠陥検出、フォトマスク修理・洗浄装置なども提供している。さらに、高度な光学蛍光顕微鏡装置、転写プロファイリングおよびマルチオーム解析のサービス、金属系低温超電導体などの超電導材料、モノリシックおよびワイヤーインチャンネル形式のマルチフィラメント丸型および角型LTS線材、キュポナールの設計・製造、金属系低温超電導体、シンクロトロンおよびビームライン装置などの非超電導ハイテクツールも提供している。ブルカー・コーポレーションは1960年に設立され、マサチューセッツ州ビレリカに本社を置いている。
Bruker Corporation 基礎のまとめ
| BRKR 基礎統計学 | |
|---|---|
| 時価総額 | US$9.07b |
| 収益（TTM） | -US$106.90m |
| 売上高(TTM) | US$3.50b |
2.6x
P/Sレシオ-84.9x
PER（株価収益率BRKR は割高か？
公正価値と評価分析を参照収益と収入
| BRKR 損益計算書（TTM） | |
|---|---|
| 収益 | US$3.50b |
| 売上原価 | US$1.80b |
| 売上総利益 | US$1.70b |
| その他の費用 | US$1.80b |
| 収益 | -US$106.90m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.70 |
| グロス・マージン | 48.48% |
| 純利益率 | -3.05% |
| 有利子負債／自己資本比率 | 75.4% |
BRKR の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.3%
現在の配当利回り-28%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/23 03:49 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bruker Corporation 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。32
| アナリスト | 機関 |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |